December 18, 2024

FDA Flags Serious Risk in Catheter Recall

The FDA has issued a 'most serious' classification for the recall of Boston Scientific's catheters used in minimally invasive surgery, linked to reports of esophageal injury and fatalities.

Reuters

December 18, 2024

Does Anger at Health Care Drive Change?

In-depth exploration of public anger towards the American health care system throughout history, potential for change, and Hollywood's portrayal of health insurance-related events.

KFF Health News

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 16, 2024

Weight-Loss Drugs Spark Health Care Shift

An exclusive analysis reveals the impact of weight-loss drugs on obesity-related conditions, leading to increased diagnoses of sleep apnea, cardiovascular disease, and type 2 diabetes within days of treatment initiation.

Reuters

April 29, 2024

Record Heat Waves Propel Surge in Heat-Related Illness

2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.

Conexiant

November 17, 2023

FDA Approves Capivasertib With Fulvestrant for Breast Cancer

On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...

The ASCO Post

July 25, 2024

Senate Investigates Bankruptcy of Hospital Chain: CEO Subpoenaed

The U.S. Senate Committee is calling the CEO of Steward Health to testify about alleged corporate greed and financial mismanagement amid the company's bankruptcy.

Reuters

August 01, 2024

Tirzepatide Reduces Heart Failure Risk by 38% in Clinical Trial

Results from a trial reveal that Eli Lilly's tirzepatide, a weight loss drug, reduces the risk of heart failure outcomes by 38% compared to a placebo for obese adults, with significant weight loss and improved symptoms. Novo Nordisk's Wegovy also shows promise in reducing heart failure symptoms.

Reuters